CoChat
Sign Up
Cited by 125Hormonal and reproductive studiesProstate Cancer Treatment and ResearchUrinary Bladder and Prostate Research

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system

Wayne Meikle, A., Arver, Stefan, Dobs, Adrian S., Adolfsson, Jan, Sanders, Steven W., Middleton, Richard G., Stephenson, Robert A., Hoover, Donald R., Rajaram, Lakshiminaryan, Mazer, Norman A.·1997·Urology
DOI 10.1016/s0090-4295(96)00445-1
Open this paper in CoChat — free account

Abstract

Objectives This study examined the effects of testosterone replacement using a nonscrotal testosterone transdermal (TTD) system on prostate size and prostate-specific antigen (PSA) levels in hypogonadal men.Methods As part of an open-label, multicenter study, prostate volume as measured by transrectal ultrasound and PSA were assessed in 29 hypogonadal men during treatment with intramuscular testosterone enanthate (+TE), followed by 8 weeks of androgen withdrawal (-T), and then during 1 year of therapy with Androderm Testosterone Transdermal System, a nonscrotal permeation-enhanced TTD system (+TTD).Results Mean prostate volume decreased significantly from the +TE period (17 g) compared with the -T period (14 g) (P < 0.001). Prostate volume increased significantly from the -T period compared with the +TTD period (18 g) (P < 0.001). Maximum prostate size, comparable to that measured during +TE (P = 0.125), was reached by month 3 of +TTD therapy; prostate volume did not increase further during the remaining 9 months of +TTD therapy. Prostate volume correlated with age (P < 0.01) during all three periods of observation (+TE: r = 0.69; -T: r = 0.64; and +TTD: r = 0.55). No patient developed symptomatic benign prostatic hyperplasia during the treatment period. PSA levels decreased during androgen withdrawal compared with levels measured during +TE treatment (P < 0.001) and rose with resumption of androgen therapy with TTD (P < 0.006). However, PSA levels during +TTD replacement remained significantly lower (P < 0.001) than during +TE replacement.Conclusions Physiologic testosterone replacement in hypogonadal men was achieved using the TTD system. Prostate size during therapy with TTD was comparable to that reported for normal men. In these men treated with TTD, PSA levels were also within the normal range.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(96)00445-1

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. Moore, 1944, Benign hypertrophy and carcinoma of the prostate. Occurrence and experimental production in animals, Surgery, 16, 152
  2. Meikle, 1996, Efficacy and safety of a nonscrotal transdermal testosterone delivery (TTD) system in hypogonadal men treated previously with testosterone injection (abstract 952), J Urol, 155, 549A

Cited by

Sorted by citations

Items 101–125 of 125

Related

See all

Metadata

Authors
Wayne Meikle, A., Arver, S., Dobs, A. S., Adolfsson, J., Sanders, S. W., Middleton, R. G., Stephenson, R. A., Hoover, D. R., Rajaram, L., & Mazer, N. A.
Affiliations
Karolinska University Hospital (SE)
ORCID
Venue
Urology
Publisher
Elsevier BV
Published
1997-02
Volume
49
Issue
2
Pages
191-196
ISSN
0090-4295 (ISSN-L)
DOI
10.1016/s0090-4295(96)00445-1
OpenAlex
W1980883512
Cited by
125
References
34
Citations by year
2024: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
6.91
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Urology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1r55dk043344-01, 5r01dk045760-04)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-43344, DK45760)
  • National Center for Research Resources (M01-RR 00064, M01RR000064)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
Keywords
testosterone replacement therapy, hypogonadism, prostate volume, prostate-specific antigen, androgen withdrawal, testosterone enanthate, benign prostatic hyperplasia
MeSH terms
Administration, Cutaneous, Adult, Aged, Humans, Hypogonadism, Male, Middle Aged, Prostate, Testosterone, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review